Trial Profile

Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
Indications Malignant thymoma
Focus Therapeutic Use

Most Recent Events

28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
15 Mar 2018 Status changed from active, no longer recruiting to recruiting.
25 Jan 2018 Results (n=41) assessing the activity of pembrolizumab, a monoclonal antibody that targets PD-1, in patients with advanced thymic carcinoma, were published in the Lancet Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com